Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy

Abstract The purpose of this study was to investigate the effects of SLC22A2 808G>T polymorphism and trough concentrations (C0) of bosutinib on serum creatinine in 28 patients taking bosutinib. At 1, 3, 6, 12, 24, and 36 months after administration, analysis of bosutinib C0 and creatinine was per...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maiko Abumiya, Naoto Takahashi, Saori Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Masatomo Miura
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/cddf7025ea95456eac4b8a2a0965cf7f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cddf7025ea95456eac4b8a2a0965cf7f
record_format	dspace
spelling	oai:doaj.org-article:cddf7025ea95456eac4b8a2a0965cf7f2021-12-02T17:05:11ZEffects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy10.1038/s41598-021-85757-72045-2322https://doaj.org/article/cddf7025ea95456eac4b8a2a0965cf7f2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85757-7https://doaj.org/toc/2045-2322Abstract The purpose of this study was to investigate the effects of SLC22A2 808G>T polymorphism and trough concentrations (C0) of bosutinib on serum creatinine in 28 patients taking bosutinib. At 1, 3, 6, 12, 24, and 36 months after administration, analysis of bosutinib C0 and creatinine was performed at the same time of day. Significant correlations were observed between bosutinib C0 and the change rate of serum creatinine or the estimated glomerular filtration rate (eGFR; r = 0.328, P < 0.001 and r = − 0.315, P < 0.001, respectively). These correlations were particularly high in patients having the SLC22A2 808G/G genotype (r = 0.345 and r = − 0.329, respectively); however, in patients having the 808T allele, there were no significant differences. In multivariate analyses, the SLC22A2 808G/G genotype, patient age, bosutinib C0 and second-line or later bosutinib were independent factors influencing the change rate of creatinine. Bosutinib elevated serum creatinine through organic cation transporter 2 (OCT2). We observed a 20% increase in serum creatinine with a median bosutinib C0 of 63.4–73.2 ng/mL. Periodic measurement of serum creatinine after bosutinib therapy is necessary to avoid progression to severe renal dysfunction from simple elevation of creatinine mediated by OCT2 following bosutinib treatment.Maiko AbumiyaNaoto TakahashiSaori TakahashiTomoko YoshiokaYoshihiro KameokaMasatomo MiuraNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Maiko Abumiya Naoto Takahashi Saori Takahashi Tomoko Yoshioka Yoshihiro Kameoka Masatomo Miura Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
description	Abstract The purpose of this study was to investigate the effects of SLC22A2 808G>T polymorphism and trough concentrations (C0) of bosutinib on serum creatinine in 28 patients taking bosutinib. At 1, 3, 6, 12, 24, and 36 months after administration, analysis of bosutinib C0 and creatinine was performed at the same time of day. Significant correlations were observed between bosutinib C0 and the change rate of serum creatinine or the estimated glomerular filtration rate (eGFR; r = 0.328, P < 0.001 and r = − 0.315, P < 0.001, respectively). These correlations were particularly high in patients having the SLC22A2 808G/G genotype (r = 0.345 and r = − 0.329, respectively); however, in patients having the 808T allele, there were no significant differences. In multivariate analyses, the SLC22A2 808G/G genotype, patient age, bosutinib C0 and second-line or later bosutinib were independent factors influencing the change rate of creatinine. Bosutinib elevated serum creatinine through organic cation transporter 2 (OCT2). We observed a 20% increase in serum creatinine with a median bosutinib C0 of 63.4–73.2 ng/mL. Periodic measurement of serum creatinine after bosutinib therapy is necessary to avoid progression to severe renal dysfunction from simple elevation of creatinine mediated by OCT2 following bosutinib treatment.
format	article
author	Maiko Abumiya Naoto Takahashi Saori Takahashi Tomoko Yoshioka Yoshihiro Kameoka Masatomo Miura
author_facet	Maiko Abumiya Naoto Takahashi Saori Takahashi Tomoko Yoshioka Yoshihiro Kameoka Masatomo Miura
author_sort	Maiko Abumiya
title	Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
title_short	Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
title_full	Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
title_fullStr	Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
title_full_unstemmed	Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
title_sort	effects of slc22a2 808g>t polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/cddf7025ea95456eac4b8a2a0965cf7f
work_keys_str_mv	AT maikoabumiya effectsofslc22a2808gtpolymorphismandbosutinibconcentrationsonserumcreatinineinpatientswithchronicmyeloidleukemiareceivingbosutinibtherapy AT naototakahashi effectsofslc22a2808gtpolymorphismandbosutinibconcentrationsonserumcreatinineinpatientswithchronicmyeloidleukemiareceivingbosutinibtherapy AT saoritakahashi effectsofslc22a2808gtpolymorphismandbosutinibconcentrationsonserumcreatinineinpatientswithchronicmyeloidleukemiareceivingbosutinibtherapy AT tomokoyoshioka effectsofslc22a2808gtpolymorphismandbosutinibconcentrationsonserumcreatinineinpatientswithchronicmyeloidleukemiareceivingbosutinibtherapy AT yoshihirokameoka effectsofslc22a2808gtpolymorphismandbosutinibconcentrationsonserumcreatinineinpatientswithchronicmyeloidleukemiareceivingbosutinibtherapy AT masatomomiura effectsofslc22a2808gtpolymorphismandbosutinibconcentrationsonserumcreatinineinpatientswithchronicmyeloidleukemiareceivingbosutinibtherapy
_version_	1718381818043957248

Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy

Ejemplares similares